FDG-PET/CT: New horizons in anal cancer

P. W. Grigsby

doi:10.1016/j.gcb.2009.01.012

FDG-PET/CT: New horizons in anal cancer

P. W. Grigsby

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries. Its incidence seems to be increasing because of exposure to human immunodeficiency virus (HIV) and human papillomavirus (HPV). Traditional pretreatment evaluations include physical examination and CT imaging of the pelvis. Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer. At diagnosis, FDG-PET/CT is used to evaluate primary tumor size, lymph node status and to evaluate for distant metastases. FDG-PET/CT can also be used for radiation therapy treatment planning by clearly defining sites of metabolically active tumor. Posttherapy FDG-PET/CT to determine response to therapy is highly predictive of long-term clinical outcomes. This imaging modality can also be used to evaluate sites of recurrent disease. FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.

Original language	English
Pages (from-to)	456-458
Number of pages	3
Journal	Gastroenterologie Clinique et Biologique
Volume	33
Issue number	5
DOIs	https://doi.org/10.1016/j.gcb.2009.01.012
State	Published - May 2009

Access to Document

10.1016/j.gcb.2009.01.012

Cite this

@article{27ee5a15206e4242939b670bbbf6753a,

title = "FDG-PET/CT: New horizons in anal cancer",

abstract = "Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries. Its incidence seems to be increasing because of exposure to human immunodeficiency virus (HIV) and human papillomavirus (HPV). Traditional pretreatment evaluations include physical examination and CT imaging of the pelvis. Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer. At diagnosis, FDG-PET/CT is used to evaluate primary tumor size, lymph node status and to evaluate for distant metastases. FDG-PET/CT can also be used for radiation therapy treatment planning by clearly defining sites of metabolically active tumor. Posttherapy FDG-PET/CT to determine response to therapy is highly predictive of long-term clinical outcomes. This imaging modality can also be used to evaluate sites of recurrent disease. FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.",

author = "Grigsby, {P. W.}",

year = "2009",

month = may,

doi = "10.1016/j.gcb.2009.01.012",

language = "English",

volume = "33",

pages = "456--458",

journal = "Gastroenterologie Clinique et Biologique",

issn = "0399-8320",

number = "5",

}

TY - JOUR

T1 - FDG-PET/CT

T2 - New horizons in anal cancer

AU - Grigsby, P. W.

PY - 2009/5

Y1 - 2009/5

N2 - Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries. Its incidence seems to be increasing because of exposure to human immunodeficiency virus (HIV) and human papillomavirus (HPV). Traditional pretreatment evaluations include physical examination and CT imaging of the pelvis. Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer. At diagnosis, FDG-PET/CT is used to evaluate primary tumor size, lymph node status and to evaluate for distant metastases. FDG-PET/CT can also be used for radiation therapy treatment planning by clearly defining sites of metabolically active tumor. Posttherapy FDG-PET/CT to determine response to therapy is highly predictive of long-term clinical outcomes. This imaging modality can also be used to evaluate sites of recurrent disease. FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.

AB - Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries. Its incidence seems to be increasing because of exposure to human immunodeficiency virus (HIV) and human papillomavirus (HPV). Traditional pretreatment evaluations include physical examination and CT imaging of the pelvis. Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer. At diagnosis, FDG-PET/CT is used to evaluate primary tumor size, lymph node status and to evaluate for distant metastases. FDG-PET/CT can also be used for radiation therapy treatment planning by clearly defining sites of metabolically active tumor. Posttherapy FDG-PET/CT to determine response to therapy is highly predictive of long-term clinical outcomes. This imaging modality can also be used to evaluate sites of recurrent disease. FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.

UR - http://www.scopus.com/inward/record.url?scp=67349232354&partnerID=8YFLogxK

U2 - 10.1016/j.gcb.2009.01.012

DO - 10.1016/j.gcb.2009.01.012

M3 - Article

C2 - 19394179

AN - SCOPUS:67349232354

SN - 0399-8320

VL - 33

SP - 456

EP - 458

JO - Gastroenterologie Clinique et Biologique

JF - Gastroenterologie Clinique et Biologique

IS - 5

ER -

FDG-PET/CT: New horizons in anal cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this